Genprex is thrilled to announce that the China National Intellectual Property Administration has granted Patent No. 201780076886.X, protecting their lead drug candidate, REQORSA Immunogene Therapy, when combined with PD1 antibodies through 2037. This approval extends patent protection already received in the U.S., Japan, Mexico, Australia and Russia, ensuring exclusivity in some of the world’s top markets.
As an added bonus, this protection guarantees Genprex’s ongoing Acclaim-2 clinical trial, which is testing REQORSA in combination with Keytruda to treat advanced, metastatic non-small cell lung cancer, from any potential competitors. This patent is sure to revolutionize cancer treatments around the world!
In 2022, Genprex received a U.S. patent granting protection for the combination of REQORSA with PD1 antibodies for the treatment of cancer. In 2021, Genprex received U.S. Food and Drug Administration’s (FDA) Fast Track Designation for treatment of the Acclaim-2 patient population.
The revolutionary Acclaim-2 trial could dramatically change the way we treat advanced, metastatic non-small-cell lung cancer. REQORSA and Keytruda are being tested in combination with other treatments in a Phase 1/2 open-label dose-escalation clinical response study. Up to 18 patients will take part in the Phase 1 dose escalation, 36 in the Phase 2 expansion, and 126 in the Phase 2 randomized portion.
Patients in the randomized portion will be assigned to receive either REQORSA and Keytruda combination therapy or chemotherapy (docetaxel with or without ramucirumab). Genprex expects to complete enrollment for the Phase 1 dose escalation by the first quarter of 2024, which could provide much needed hope to people living with this disease.
About Genprex, Inc.
Genprex is revolutionizing the approach to treating cancer and diabetes with their clinical-stage gene therapy technology. With their ONCOPREX® Nanoparticle Delivery System, their REQORSA® product candidate is being tested in three clinical trials to enhance treatment options for NSCLC and SCLC patients. What’s even more amazing, the Food and Drug Administration has granted Fast Track Designation for each of these clinical programs.
Not just that, the Company is also exploring gene therapy approach to diabetes with GPX-002 and GPX-003 that use adeno-associated virus (AAV) vectors to deliver gene therapies tailored to both Type 1 and Type 2 diabetes directly to the pancreas. GPX-002 and GPX-003 potentially transform alpha cells in the pancreas into beta-like cells and rejuvenate and replenish exhausted beta cells respectively. This can serve as an immense breakthrough in the field of healthcare and medicine change the course of treatment for cancer and diabetes patients.
Cautionary Language Concerning Forward-Looking Statements
Genprex is committed to driving the clinical development, manufacturing, and commercialization of its groundbreaking product candidates with the goal of advancing the fight against cancer and diabetes. With its strong strategic partnerships, impressive intellectual property, and long-term financing, Genprex stands ready to make a real difference in medical treatments.
Our commitment to innovation will ensure that we are at the forefront of pioneering new medications, and our technology and resources will guarantee that we remain there. With continued investment and dedication, Genprex is poised to help people around the world through the use of cutting-edge treatments and therapies.
Forward-looking statements are not guarantees; they can be inaccurate at times. Don’t be fooled; Genprex cannot guarantee any events or circumstances discussed in these statements will be achieved or take place. Genprex cannot promise that its objectives and plans will be fulfilled in any specified timeframe, or even at all.
Take caution when relying on these statements as reflections and warranties. This press release only speaks for itself at the time of date the press release goes out. Genprex is obligated to update or otherwise release any revisions to these forward-looking statements. Such revisions may take into account new information, future events, and other unknown circumstances. Unless otherwise required by law, Genprex disclaims any obligation or decision to make such revisions.